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Background: Venous thromboembolism (VTE) is a serious, yet preventable, complication
in cancer. Some patients are diagnosed with a second cancer; however, little is known about
the epidemiology of VTE in this population.
Methods: From Danish national healthcare registries, we studied all patients diagnosed with
a first breast, prostate, lung, or colorectal cancer from 1995 to 2015. We estimated incidence
rates (IRs) of VTE according to the timing of the diagnosis of a second cancer. We controlled
for confounder variables in Poisson regression models.
Results: In total, 309,077 patients with a first breast, prostate, lung, or colorectal cancer
were included in the study. A second cancer was diagnosed in 20,090 (6.5%) of these
patients. In total, 11,908 VTEs were observed in the study period, 786 of these occurred
after a diagnosis of second cancer. Second cancer types such as pancreas and stomach cancer
were associated with fivefold higher IRs of VTE compared with second cancer types such as
breast and prostate cancer. The IR of VTE was highest within the first 6 months after the
second cancer was diagnosed (IR 40.5 per 1000 person-years, 95% CI 36.3–42.2) with no
differences based on how long since the first cancer it was diagnosed.
Conclusion: The epidemiology of VTE after a second cancer is similar to the epidemiology
of VTE after a first cancer with higher rates within the first months after aggressive second
cancer types.
Keywords: venous thromboembolism, second cancer, epidemiology, incidence, cancer
Introduction
Venous thromboembolism (VTE) is a frequent complication of cancer that leads to
mental and physical morbidity and results in high mortality rates.1–5 Cancer survi-
val rates have continuously increased due to accelerated diagnostic work-up and
successively refined cancer treatments.6,7 Despite these improvements for cancer
patients, little is known about their long-term risk of VTE. This growing group of
patients, however, represents a considerable proportion patients with VTE, and
some of these patients develop a second cancer.8–12 The epidemiology of VTE in
cancer patients who develop a second cancer has not been previously described.
The aim of this study was to investigate the epidemiology of VTE among
patients diagnosed with a second cancer. We used data from Danish nationwide
healthcare registers where diagnoses, procedures, and information about reimbursed
medicine are prospectively registered at an individual level. This provides unique
opportunities for epidemiological research.13–15
Our hypothesis was that cancer patients who develop a second cancer had a
higher risk of VTE than patients with only one cancer. We investigated the risk of
Correspondence: Inger Lise Gade
Department of Hematology, Aalborg
University Hospital, Mølleparkvej 4,
Aalborg 9000, Denmark
Tel +45 61656584
Email inlg@rn.dk
Clinical Epidemiology Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Clinical Epidemiology 2020:12 377–386 377
http://doi.org/10.2147/CLEP.S247823
DovePress © 2020 Gade et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
7.
10
1.
74
 o
n 
30
-A
pr
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
VTE based on the timing of the second cancer diagnosis in
the subset of the general population diagnosed with a first
breast, prostate, lung, or colorectal cancer between 1995
and 2015 from the Danish National Cancer Registry, the
Danish National Patient Registry (DNPR), and the Danish
National Prescription Registry. Estimates of VTE risk
were calculated separately for the following periods after
the first and second cancer diagnosis: 0–6 months, 6–12
months, 1–2 years and >2 years.
Methods
Setting
There are approximately 5.5 million people in the Danish
population. The Danish Civil Registration system keeps
track of the Danish residents’ vital status and movement
within the Danish border and abroad. This is possible by
assigning a unique civil personal registration (CPR) num-
ber to all Danish residents at birth or at the time of
immigration. The unique CPR number enables linking of
information from all Danish registries and cradle-to-grave
follow-up at an individual level.14
Danish residents have income-independent access to uni-
versal healthcare. The Danish healthcare system is tax-funded
based on individual contacts registered with the CPR number.
Hospital admissions, diagnoses, surgeries, and therapies for
each contact have been recorded in the DNPR since 1977.
Until 1994, the International Classification of Diseases codes
—8th edition (ICD-8 codes)—were used for classification of
the diagnoses. From 1994 onwards, the ICD-10 classification
has been used in the DNPR. Surgeries are registered in the
DNPR by the Nordic Medico Statistical Committee
(NOMESCO)16 classification. Since 1995, contacts to out-
patient clinics and emergency departments have also been
prospectively registered in the DNPR. More than 99% of all
contacts to the Danish healthcare system are captured in the
DNPR.13,17
Study Population
We included all Danish residents diagnosed with a first
primary breast, prostate, lung, or colorectal cancer between
1995 and 2015. Since 1987, the registration of new cancer
cases plus certain tumor-like and benign lesions in the Danish
National Cancer Registry has been mandatory by law and
linked to the DNPR. The Danish National Cancer Registry
captures more than 95% of all new cancer cases, and 93% of
the diagnoses are verified by microscopy.15,18 Study patients
were identified in the DanishNational Cancer Registry by the
ICD-10 codes C34.0–34.9 for lung cancer, C61.0–61.9 for
prostate cancer, C50.0–50.9 for breast cancer, and C18.0–
21.9 for colorectal cancer. The last available date of cancer
registration was December 31, 2015.
Exposure
Second cancer was identified by the combination of the
procedure code AZCA1 in the DNPR, which is used for
new malignant diseases not fully registered previously in
the Danish National Cancer Registry, and an ICD-10 code
within the C00-97 group in the Danish National Cancer
Registry. If the second registration was within the same
ICD-10 group as the first cancer, we considered the patient
as having progression/relapse of the first cancer and did
not classify patients as having developed a second cancer.
Carcinoma in situ, non-melanoma skin cancer, and benign
tumors were excluded. Second cancers were classified as
either very high VTE-risk, high VTE-risk, or intermediate/
low VTE-risk based on published risk assessment models
for prediction of VTE in cancer patients (Supplementary
Table 1).19,20
Outcome and Confounders
Outcome was VTE after a first diagnosis of breast, pros-
tate, lung or colorectal cancer. The VTEs were identified
by linkage to the DNPR (ICD-10 I26, I80.0-I80.9). Last
date for follow-up of VTE was December 31, 2017. Due to
the low positive predictive value of VTE diagnosis codes
from emergency departments,21 we excluded events that
were not subsequently coded in a ward or an outpatient
clinic.
VTEs preceding the first cancer diagnosis were identified
by the ICD-8 codes 450 and 451 in addition to the aforemen-
tioned ICD-10 codes for VTE in the DNPR. Information
about anticoagulation medication was retrieved from the
Danish National Prescription Registry, in which the type of
medicine is registered with the World Health Organization’s
Anatomical Therapeutic Chemical codes along with dose,
pack size and date of reimbursement.22 We used the
Anatomical Therapeutic Chemical codes B01AA03,
B01AE07, B01AF02, B01AF01, B01AB10, B01AB04, and
B01AB05 to identify anticoagulation treatment. If patients
were hospitalized and had a period of anticoagulation treat-
ment, they were considered “anticoagulated” during the hos-
pitalization. Information about hospitalization admission and
discharge dates was retrieved from the DNPR.
Lower extremity fractures (ICD-10 codes T02, S72,
S82, S92) and arthroplasties including surgical revisions
Gade et al Dovepress
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(NOMESCO codes NFB, NFC, NGB and NGC) after the
first cancer diagnosis were identified in the DNPR.
Study Design and Statistics
Study entry was the date of diagnosis of one of the studied
first cancer types, patients were followed until whichever
of the following came first: death, VTE, emigration, or
administrative censoring (ie, last follow-up for cancer was
December 31, 2015). The patients who were diagnosed
with a second cancer during follow-up shifted to contri-
bute with person-time at risk of VTE in the group with a
second cancer from the date of the second cancer diagno-
sis onwards. One day of observation time was given in
cases where cancer and VTE were diagnosed on the same
date.
Estimates of absolute risk of VTE were measured using
incidence rates (IRs) of VTE expressed as events per 1000
person-years (p-y) and associated 95% confidence inter-
vals (CIs). We calculated IRs of VTE in patients with only
one cancer and in patients diagnosed with a second cancer.
We calculated IRs of VTE for second cancers diagnosed
within the following four periods: 0–6 months, 6–12
months, 1–2 years and >2 years after the first cancer. We
calculated IR’s of VTE by increasing time since diagnosis
of first and second cancer, respectively. Additionally, we
calculated IRs of VTE according to the second cancers’
VTE risk category.
Incidence rate ratios (IRRs) of VTE were estimated
using Poisson regression models, including pre-determined
time-dependent covariates. Covariates included the second
cancer VTE risk group, time since first cancer diagnosis,
calendar period, and time since second cancer diagnosis.
We defined the following risk periods after the first and
possibly second cancer diagnosis: 0–6 months, 6–12
months, 1–2 years and >2 years. Patients who received
anticoagulant medication in the study period changed from
“not on anticoagulation medication” to “on anticoagulation
medication” on the date of first reimbursed prescription,
and changed back to “not on anticoagulation medication”
status on the date of calculated last anticoagulation medi-
cine dose. Regarding the covariates fractures and arthro-
plasties, we defined the 90 days following the diagnosis/
operation day as the exposed time in accordance with the
definition of transient risk factors by the International
Society of Thrombosis and Haemostasis.23 Age was
included as a categorical time-dependent variable, and
sex and a history of VTE before study entry were included
as dichotomous variables.
In a sensitivity analysis, we excluded patients with a
history of VTE before study entry.
Ethics
Neither ethical approval nor informed consent is not
required for studies based on Danish register data if con-
ducted for the sole purpose of statistics and scientific
research. The study was approved by the data responsible
institute (Region Hovedstaden – Approval number
P-2019-348) in accordance with the General Data
Protection Regulation.
Results
Patient Characteristics
A total of 309,077 patients were diagnosed with either a first
breast (n = 86,632), prostate (n = 64,381), lung (n = 77,791),
or colorectal cancer (n = 80,275) from 1995 to 2015
(Supplementary Figure 1). The median age at study entry
was 70.0 years (25th–75th percentile, 60.2–76.9) and 52%
were women (Table 1). In 10,689 of the study patients, a VTE
was registered before the first cancer diagnosis; however, 988
of these VTEs were solely coded in an emergency depart-
ment. Thus, in total, 9701 study patients were diagnosed with
a VTE prior to the first cancer diagnosis (519 concurrent
pulmonary embolism and deep vein thrombosis, 2559 pul-
monary embolisms and 6623 deep vein thromboses). Median
time from the previous VTE to first cancer diagnosis was 6.7
years (25th–75th percentile 2.0–14.3 years). The median
follow-up time was 2.4 years (25th–75th percentile, 0.6–6.5
years).
Exposure
A second cancer was diagnosed in 6.5% (20,090) of the
study patients, most frequently after a first colorectal or
prostate cancer (Table 2). Seven percent (1431) of the
second cancers were classified as very high VTE-risk
cancer types, 77.6% (15,592) as high VTE-risk second
cancers, and 15.3% (3067) as intermediate/low VTE-risk
cancers. The proportion of intermediate/low VTE-risk sec-
ond cancers was lower in patients with a first prostate and
breast cancer than in patients with a first lung or colorectal
cancer because the vast majority of intermediate/low VTE-
risk second cancers were either prostate or breast cancer.
Outcome
A total of 11,918 VTEs were observed after study entry
following exclusion of 1152 VTEs that were coded solely
Dovepress Gade et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
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in an emergency department. Ten patients emigrated after
a first cancer diagnosis and were years later diagnosed
with a VTE after returning to Denmark. These 10 events
were not included in the analysis because we did not have
data concerning possible second cancer development dur-
ing their emigration period. Thus, 11,908 VTEs remained
in our study (393 concurrent pulmonary embolism and
deep vein thrombosis, 5526 pulmonary embolisms and
5989 deep vein thromboses) (Supplementary Figure 1).
Twelve percent (1400) of the VTEs occurred in patients
with a history of VTE before study entry. For further
details, see supplemental results. The overall IR of VTE
in the study was 9.1 per 1000 p-y (95% CI, 8.9–9.3).
First Cancer and VTE in Unexposed
Patients
The overall IR of VTE among patients without a second
cancer was 8.9 per 1000 p-y (95% CI, 8.8–9.1); however,
there were large variations based on the type of first cancer
and time since it was diagnosed. Please see supplemental
results for detailed description (Table 3, Figure 1).
Second Cancer and VTE
The overall IR of VTE in patients after diagnosis of a
second cancer was 20.9 per 1000 p-y (95% CI, 19.4–22.3);
however, there was considerable variation based on time
since diagnosis and the type of the second cancer.
The IRs of VTE were markedly higher for very
high VTE-risk second cancer types than high - and inter-
mediate/low VTE-risk second cancers (Figure 2,
Supplementary Table 2). Very high VTE-risk second can-
cer was associated with a 5-fold higher risk of VTE than
an intermediate/low VTE-risk second cancer in multivari-
ate analysis accounting for: type of and time since first
cancer diagnosis; time since second cancer diagnosis; and
patient-related factors such as age, sex, anticoagulation
treatment, previous VTE, arthroplasties and fractures
(Figure 3).
The IR of VTE was highest within the first 6 months
after a second cancer diagnosis. We observed similar 0–6
month IR’s for second cancers diagnosed within the first
six months after the first cancer diagnosis and second
cancers diagnosed later after the first cancer (Figure 1,
Table 3). The impact of a second cancer on the risk of
VTE declined with time since the second cancer diagnosis.
This association was confirmed by the multivariate analy-
sis where the IRR of VTE more than two years after the
second cancer diagnosis was 0.32 (95% CI, 0.23–0.47)
compared with the first 0–6 months after the second cancer
diagnosis (Figure 3). Please see supplemental results for
further description.
The impact of a second cancer on the IR of VTE was
more pronounced in patients with a first intermediate/low
VTE-risk cancer type (ie a first prostate or breast cancer)
Table 1 Patient Characteristics According Exposure to Second
Cancer in the Study Period, Person-Years (%)
Variable Second Cancer
No
(n= 288,987)
Yes
(n=20,090)
Sex
Male 488,950 (96.3) 18,761 (3.7)
Female 777,207 (96.9) 24,650 (3.1)
Age groups
<50 years 130,577 (98.1) 2491 (1.9)
50–65 years 397,420 (97.8) 9128 (2.2)
66–80 years 537,683 (96.0) 22,403 (4.0)
>80 years 200,476 (95.5) 9389 (4.5)
Calendar Period
1995–1999 87,853 (98.9) 949 (1.1)
2000–2004 215,895 (98.1) 4102 (1.9)
2005–2009 346,537 (97.1) 10,520 (2.9)
2010–2016 615,871 (95.7) 27,839 (4.3)
First Cancer Type
Prostate 277,223 (97.0) 8701 (3.0)
Breast 559,518 (97.2) 16,037 (2.8)
Lung 106,012 (97.2) 3096 (2.8)
Colorectal 313,403 (95.3) 15,541 (4.7)
Before Possible Exposure to Second
Cancer
First cancer only 1,266,157
Second cancer type
Intermediate/low VTE-risk second
cancera
8810
High VTE-risk second cancerb 33,323
Very high VTE-risk second cancerc 1235
Lower Extremity Fracture
No 1,261,200 (96.7) 43,188 (3.3)
Yes 4957 (95.7) 223 (4.3)
Arthroplasty
No 1,263,424 (96.7) 43,302 (3.3)
Yes 2734 (96.2) 109 (3.8)
A History of VTE Before First Cancer
No 1,241,547 (96.7) 42,615 (3.3)
Yes 24,611 (96.9) 796 (3.1)
Notes: aBreast, prostate, indolent lymphoma, chronic leukemias. bLung, colorectal,
esophagus, kidney, aggressive lymphoma, myeloma, bladder, testicular, gynecologic,
other types. cStomach, pancreas, brain.
Gade et al Dovepress
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than in patients with a first high VTE-risk cancer type (ie a
first lung and colorectal cancer). In patients with a first
prostate or breast cancer, second cancer lead to markedly
higher IRs of VTE than in patients with only prostate or
breast cancer regardless of the timing of diagnosis of the
second cancer (Table 3). Contrarily, similar 0–6 month IRs
of VTE was observed for patients with only lung or color-
ectal cancer and those who were diagnosed with a second
cancer within the first six months after the lung cancer
diagnosis. For those with a first lung cancer even if diag-
nosed with high/very high VTE-risk second cancer types
(0–6 month IR of VTE: 55.0, 95% CI, 27.5–110.0). If a
second cancer was diagnosed more than one year after a
first lung or colorectal cancer diagnosis; however, the IR
was higher than in patients free of second cancer (Table 3).
The impact of a second cancer on the risk of VTE in
cancer patients was surpassed by exposure to lower
extremity fractures (IRR of VTE in exposed period
compared with unexposed 12.3, 95% CI, 9.7–15.6),
arthroplasties (IRR of VTE in exposed period compared
with unexposed 13.8, 95% CI, 10.2–18.5), and a history
of VTE (IRR of VTE in patients with a history of VTE
compared with no VTE before first cancer 10.8, 95% CI
9.4–12.5) in the multivariate analysis (Supplementary
Figure 2).
Exclusion of patients with a history of VTE did not
alter the observed associations. The IRs of VTE were
generally marginally lower in the sensitivity analysis
than in the primary analysis. Largest difference was seen
in the IR of VTE within 0–6 months after a first lung
cancer diagnosis (primary analysis: IR in unexposed
patients 65.6, 95% CI, 61.7–67.8; sensitivity analysis: IR
in unexposed patients 54.3, 95% CI, 52.5–57.2) (Table 3
and Supplementary Table 3). Similarly, the association
with second cancer remained in the sensitivity analysis
after adjustment for confounder variables; IRR of VTE
in very high VTE-risk second cancer compared with unex-
posed patients was 4.66 (95% CI, 2.71–8.04)
(Supplementary Figure 3).
Discussion
This nationwide study on VTE among 309,077 patients
diagnosed with a first breast, prostate, lung, or colorectal
cancer in the period between 1995 and 2015 had two key
findings. First, the impact of a second cancer on the IR of
VTE was dependent on the type of second cancer and the
time since second cancer diagnosis. The association was
strongest for very high VTE-risk second cancer types such
as pancreatic and stomach cancers within the first months
after the second cancer diagnosis. Second, the impact of a
Table 2 Distribution of Very-High VTE Risk, High VTE Risk and Intermediate/Low VTE Risk Second Cancers by Type of First Cancer
and Time Since Diagnosis Hereof, n (% of Total)
Type of First Cancer Total, n (% of
Vertical Totals)
Time Since First Cancer Diagnosis, n (% of Horizontal Totals)
0–6 Months 6–12 Months 1–2 Years >2 Years
Breast, total 86,631
Intermediate/Low VTE-risk second cancer typesa 251 (0.3) 25 (10.0) 18 (7.2) 25 (10.0) 183 (72.9)
High VTE-risk second cancer typesb 6028 (7.0) 549 (9.1) 246 (4.1) 507 (8.4) 4726 (78.4)
Very-high VTE-risk second cancer typesc 465 (0.5) 28 (6.0) 31 (6.7) 53 (11.4) 353 (75.9)
Prostate, total 64,381
Intermediate/Low VTE-risk second cancer typesa 239 (0.4) 31 (13.0) 13 (5.4) 31 (13.0) 164 (68.6)
High VTE-risk second cancer typesb 4381 (6.8) 772 (17.6) 345 (7.9) 618 (14.1) 2646 (60.4)
Very-high VTE-risk second cancer typesc 449 (0.7) 73 (16.3) 46 (10.2) 69 (15.4) 261 (58.1)
Colorectal, total 80,275
Intermediate/Low VTE-risk second cancer typesa 1917 (2.4) 342 (17.8) 120 (6.3) 209 (10.9) 1246 (65.0)
High VTE-risk second cancer typesb 4057 (5.1) 1032 (25.4) 226 (5.6) 370 (9.1) 2429 (59.9)
Very-high VTE-risk second cancer typesc 373 (0.5) 74 (19.8) 30 (8.0) 48 (12.9) 221 (59.3)
Lung, total 77,790
Intermediate/Low VTE-risk second cancer typesa 660 (0.9) 285 (43.2) 50 (7.6) 73 (11.1) 252 (38.2)
High VTE-risk second cancer typesb 1126 (1.5) 425 (37.4) 101 (9.0) 120 (10.7) 480 (42.6)
Very-high VTE-risk second cancer typesc 144 (0.2) 46 (31.9) 19 (13.2) 22 (15.3) 57 (39.6)
Notes: aBreast, prostate, indolent lymphoma, chronic leukemias. bLung, colorectal, esophagus, kidney, aggressive lymphoma, myeloma, bladder, testicular, gynecologic, other
types. cStomach, pancreas, brain.
Dovepress Gade et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
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second cancer on the IR of VTE was dependent on the
type of patient’s first cancer and timing of the second
cancers diagnosis. A second cancer did not markedly
alter the risk of VTE for patients with a newly diagnosed
high VTE-risk first cancer type, while second cancers
diagnosed later or in patients with even newly diagnosed
low VTE-risk first cancers was associated with markedly
higher IRs of VTE.
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Figure 1 Incidence rates of VTE by time since first cancer according to time since second cancer, if exposed in the period.
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Figure 2 Incidence rates of VTE by time since second cancer diagnosis for each of the three second cancer VTE-risk groups.
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Our observations concerning second cancer and cancer
associated VTE are first in class. The associations with type
and time since second cancer diagnosis and risk of VTE
observed in this study are, however, a spitting image of
well-known effects of type of and time since first cancer and
VTE.24–30 Development of second cancer is associated with
increased risk of VTE recurrence.31,32We found that exposure
to a second cancer also increases the risk of a first incident
VTE in cancer patients, which is new and important informa-
tion for both clinicians and researchers within the field of
cancer associated thrombosis, obvious as it might seem. Our
paper for the first time confirms what is possibly already
presumed as common sense or biological plausible based on
knowledge of the pathophysiology of cancer-associated VTE.
Based on our observations in this study, we propose that
clinicians should consider thromboprophylaxis for patients
who are diagnosed with a second cancer in the same way
that thromboprophylaxis is considered for first cancer cases.
In addition, we suggest that cancer patients who undergo
arthroplasty, get a lower extremity fracture and those with a
history of VTE before the cancer diagnosis undergo careful
evaluation of the benefit of prophylactic anticoagulant treat-
ment, as they are at a particularly higher risk of VTE than
cancer patients without these risk factors. Cancer is generally
considered a high-risk factor in guidelines for the prophylaxis
of surgical thrombosis.33,34
We found a markedly higher risk of VTE as long as 6
months after both first and second cancer diagnoses in a multi-
variate analysis. Is has been estimated that 70% of all VTEs
are hospital acquired.35 In a recent Australian study, Stubbs
et al found that the risk of hospital-acquired VTE was mark-
edly higher for cancer patients than cancer-free patients.36
Four weeks of postoperative thromboprophylaxis is currently
recommended for both open - and laparoscopic cancer surgery
in the Danish guidelines, that are based on international
guidelines.37–39 The Australian data showed that the risk of
hospital acquired VTE while still hospitalized was indeed
higher for surgical patients than for medical patients.
Interestingly, the risk of VTE was markedly higher for at
least 90 days after hospital discharge for medical patients
compared with surgical patients.36 Current Danish guidelines
suggest in-hospital thromboprophylaxis for immobilized, hos-
pitalized medically ill cancer patients. Future research should
aim at identifying subgroups of medically ill, hospitalized
cancer patients who might benefit from thromboprophylaxis
after discharge.
In our study design, we took advantage of the oppor-
tunities provided by high-quality person-time data from
the Danish national healthcare registries, including all
follow-up data. Invalid VTE diagnoses were excluded
before data analysis, exposures, and relevant confounder
variables were allowed to vary over time. Despite these
Figure 3 Crude and adjusted incidence rate ratios (IRR) of VTE, adjusted estimates are depicted in the forest plot.
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advantages, our study has important limitations to bear in
mind. First, we did not include information about che-
motherapy, as this information is not validated for all
cancer types. In a previous study concerning VTE in
chronic lymphocytic leukemia patients, we observed an
apparent under-reporting of traditional chemotherapy and
antibody-based regimens for this patient group.40
Some of the very-high VTE-risk second cancers were
diagnosed in close timely relation to the first cancer and, in
some of these cases, a VTE may have been registered
before the second cancer was diagnosed. This would
draw our observations towards the null-hypothesis of no
differences in VTE occurrence in patients who develop a
second cancer and those who do not and, hence, under-
estimate the impact of a second cancer on the risk of VTE.
The reported increased IRs of VTE in patients diagnosed
with a second cancer in our study are thus conservative
estimates of the impact of development of a second cancer
on the risk of VTE.
Future studies on cancer-associated VTE, both short-
and long-term, should address possible second cancers, as
they are frequent after some cancer types and can have a
significant effect on the risk of VTE. The impact of a
second cancer on the risk of cancer-associated VTE
needs investigation, as prevention strategies could be
appropriate for certain groups. The results from this
study, however, need confirmation in other cohorts includ-
ing other types of first cancers.
In conclusion, we examined the epidemiology of can-
cer-associated VTE with regards to diagnoses of a second
cancer. Patients diagnosed with a second cancer had higher
IRs of VTE in general. The IR of VTE was highest in very
high/high VTE-risk second cancer types within the first six
months after the second cancer diagnosis.
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